Exendin-4 stimulates insulin secretion, suppresses glucagons secretion, increases β-cell replication and neogenesis, and reduces β-cell apoptosis. However, it has been shown that posttransplant exendin-4 treatment did not improve glucose homeostasis in diabetic mice transplanted with a large number of freshly isolated islets. The aim of this study was to test if exendin-4 is beneficial for hyperglycemic recipients with a marginal number of fresh islets. We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks. Before and after transplantation, recipients' blood glucose, body weight, and intraperitoneal glucose tolerance test were measured. At 6 weeks, the grafts were removed to determine β-cell mass. Blood glucose levels in both groups decreased progressively after transplantation, and the exendin-4-treated group had had lower blood glucose than controls since day 3. By 6 weeks, euglycemia was achieved more in mice treated with exendin-4 than in controls (100% vs. 62.5%, p = 0.018). The time to obtain normoglycemia was shorter in the exendin-4-treated group than in controls (12 ± 8 vs. 29 ± 13 days, p < 0.001). Blood glucose at 6 weeks was 123 ± 18 and 170 ± 62 mg/dl in the exendin-4-treated group and controls, respectively (p = 0.008). Additionally, the exendin-4-treated group had better glucose tolerance than controls at 2 and 4 weeks (p < 0.02). However, both groups exhibited increased body weight over time, and weight changes did not significantly differ between the two groups throughout the study period. At 6 weeks after transplantation, grafts in the exendin-4-treated group were more prominent and contained more insulin-stained cells than those of controls. They had 2.3-fold β-cell mass of the graft compared with controls (0.30 ± 0.11 vs. 0.13 ± 0.03 mg, p = 0.012). These results indicate posttransplant exendin-4 treatment in the diabetic recipient with a marginal number of fresh islets expands graft β-cell mass and improves transplantation outcome.
INTRODUCTION
efforts to expand the human donor pool, modify islet processing and preservation methods, as well as identify alternative islet sources (28). Another important approach Recently, the Edmonton Protocol has markedly improved the success rate of human islet transplantation is the generation of new β-cells either from preexiting βcells or from progenitor/stem cells. Recent studies have (30) . However, two or more pancreases are usually required to achieve normoglycemia. Moreover, long-term shown that, even in patients with longstanding type 1 diabetes, the endogenous pancreas maintains the ability function of the transplanted islets has been disappointing; only 10% of patients maintain insulin independence to resupply, but new insulin-producing cells to compensate for β-cell mass are lost as a consequence of autoim-5 years after transplantation (29, 31) . Allograft failure may be due to nonimmunological (e.g., insufficient βmune injury (24) . The glucagon-like peptide (GLP)-1 improves glycemic control in type 2 diabetic patients cell mass and islet engraftment problems) as well as immunological (e.g., immune rejection, toxicity of immu-by stimulating glucose-dependent insulin secretion and biosynthesis and by suppressing glucagon secretion, gas-nosuppressants, and autoimmune recurrence) factors. To improve the outcome of islet transplantation, these prob-tric emptying, and appetite (8, 9) . Additionally, GLP-1 is also known to expand β-cell mass by stimulating β-cell lems have been intensively investigated (28).
The shortage of human donor pancreata has prompted proliferation and inhibiting β-cell apoptosis (2,7,23,34). However, clinical application of native GLP-1 is limited Islet Transplantation due to its very short plasma half-life (19) .
One hundred and fifty C57BL/6 mouse islets were Exendin-4 (exenatide) is a GLP-1 mimetic resistant syngeneically transplanted under left kidney capsule of to dipeptidyl peptidase-IV-mediated inactivation and the inbred streptozotocin-diabetic mice on the same day thus exhibits more sustainable effects (13) . It also has as the isolation. Blood glucose and body weight were the ability to expand β-cell mass via stimulation of βmeasured periodically after transplantation and normogcell replication and neogenesis (2, 21, 23, 27, 35, 36) as lycemia was defined as nonfasting blood glucose levels well as prevention of β-cell death (2,5, 22, 33) . A recent <200 mg/dl (16, 17) . study demonstrated that, in diabetic mice, syngeneic
Exendin-4 Treatment transplantation of islets precultured with exendin-4 increases the reversal rate of hyperglycemia. In contrast, After islet transplantation, 16 recipients were treated posttransplant exendin-4 treatment did not improve gluwith exendin-4 (Sigma Immunochemicals), 3 µg/kg bid cose homeostasis in diabetic recipients initially trans-SC, for 6 weeks. Seventeen recipients that had not replanted with a large number of freshly isolated islets ceived exendin-4 served as controls (11) . (20). Because transplantation of additional islets can en-Intraperitoneal Glucose Tolerance Test (IPGTT) hance the growth and function of the islet graft (15, 16, 26) , the beneficial effects of exendin-4 can be After an overnight fast, a 5% glucose solution (1.5 g/ masked. Therefore, in the present study, we tested if kg) was injected intraperitoneally, and blood glucose posttransplant exendin-4 treatment in the recipient with was measured at 0, 30, 60, 90, and 120 min by tail snipa marginal number of fresh islets expands graft β-cell ping. The IPGTT was performed at 2, 4, and 6 weeks mass and improves transplantation outcome.
after transplantation (15, 17) .
Removal of the Islet Graft MATERIALS AND METHODS
Six weeks after transplantation, animals intended for Animals graft removal were anesthetized with amobarbital. An Per previous studies (16, 17) , male inbred C57BL/6 abdominal incision was made and the kidney was exmice (National Laboratory Animal Center, Taipei, Taiposed. Under dissecting microscope, the kidney capsule wan), aged 8-12 weeks, were used as transplantation surrounding the graft was excised and removed with the donors and recipients. The recipients were made diabetic adherent graft (15) . The weight of each graft was deterby a single IP injection of streptozotocin (STZ, Sigma mined on a Mettler balance type AE200 (Mettler Instru-Immunochemicals, St. Louis, MO, USA; 200 mg/kg ments Corp., NJ, USA). body weight, freshly dissolved in citrate buffer, pH 4.5). Before transplantation, diabetes was confirmed by the Immunohistochemistry and β-Cell Mass presence of hyperglycemia, weight loss, and polyuria.
of the Islet Graft Only those mice with blood glucose above 350 mg/dl at The removed grafts were fixed in formalin solution 2 weeks after STZ injection underwent transplant. Blood and processed for paraffin embedding and sectioning. glucose values were determined on blood obtained from Sections of grafts were stained for the endocrine β-cells the tail incision, with measurements performed with a with immunoperoxidase by a guinea pig anti-swine insuportable glucose analyzer (One Touch II, Lifescan Inc., lin antibody (Dako Co., Ltd, Denmark). Graft β-cell Milpitas, CA, USA). The animal experiments were apmass was measured by point counting morphometry on proved by the local animal ethics committee.
immunoperoxidase-stained sections. Each section was covered systematically using a 48-point grid to obtain Islet Isolation the number of intercepts over β-cells, endocrine non-β-Under anesthesia with sodium amobarbital, pancrecells, and other tissue. The β-cell relative volume was ases were distended with 2.5 ml of RPMI-1640 medium calculated by dividing the intercepts over β-cells by in-(GIBCO BRL, Grand Island, NY, USA) containing 1.5 tercepts over total tissue; β-cell mass was then estimated mg/ml of collagenase (collagenase from Clostridium by multiplying β-cell relative volume by graft weight histolyticum, type XI, Sigma Immunochemicals), ex- (15) (16) (17) . cised, and incubated in a water bath at 37°C. The islets Insulin Content of the Pancreas were separated by a density gradient (Histopaque-1077; Sigma Immunochemicals), and purified islets were then At 6 weeks after transplantation, the pancreases of normoglycemic recipients were removed, minced, and handpicked under a dissecting microscope (16, 17) . Islets >75 and <250 µm in diameter were collected and care-homogenized in acid ethanol. After homogenization, the samples were extracted overnight at 4°C. On the follow-fully counted into groups of 150 islets.
ing day, they were centrifuged at 2400 rpm for 30 min, Metabolic Evolution of Recipients After Islet Transplantation and the supernatant was stored at −20°C. The pellet was rehomogenized in acid ethanol and insulin extracted Blood glucose levels in both groups decreased proovernight. After centrifugation, this second supernatant gressively after transplantation. However, the exendinwas added to the first extraction sample and kept in a 4-treated group had lower blood glucose than controls −20°C freezer until assay. Insulin was measured by ra- (Fig. 1) . By 6 weeks, euglycemia was achieved in 15/ dioimmunoassay (rat insulin RIA, Linco Research, St.
15 (100%) of mice treated with exendin-4 versus 10/16 Charles, MO, USA). Because the mouse with pancreatic (62.5%) of controls (p = 0.018) (Fig. 2) . Normoglyinsulin of 83.44 ng was still diabetic in this series, β-cell cemia was observed at 12 ± 8 days in the exendin-4regeneration in the endogenous pancreas was considered treated group and at 29 ± 13 days in controls (p = 0.000). insignificant if the mouse pancreas had value equal or Blood glucose at 6 weeks was 123 ± 18 and 170 ± 62 below this cutoff. The mice with the evidence of endogmg/dl in the exendin-4-treated group and controls, reenous β-cell regeneration were excluded from the study. spectively (p = 0.008). Additionally, the exendin-4-treated group had better glucose tolerance than the control Statistical Analysis group at 2 and 4 weeks (p < 0.02) ( Fig. 3 ). However, in both groups, body weight increased over time, and the Results were expressed as mean ± SD. Unpaired Stuchange in body weight did not significantly differ bedent's t-test, chi square test, and Kaplan-Meier curve tween the two groups throughout the study period. At 6 were employed to compare two groups. A value of p < weeks, body weight was 24.8 ± 1.0 and 24.4 ± 2.3 g 0.05 was considered significant.
(p = 0.562), and weight gain was 3.4 ± 1.7 and 2.6 ± 1.9 g (p = 0.198) in the exendin-4-treated group and con-RESULTS trols, respectively. The possibility of β-cell regeneration in the endogenous pancreas was evaluated by measuring pancreatic Morphology and β-Cell Mass of the Graft insulin content in recipients achieving normoglycemia. One recipient in each group had pancreatic insulin con-At 6 weeks after transplantation, grafts in the exendin-4-treated group were more prominent than those of tent greater than 83.44 ng and were excluded from the study. Finally, there were 15 and 16 animals in exendin-controls. Graft immunohistochemistry revealed a larger number of insulin-stained cells in the exendin-4-treated 4-treated group and controls, respectively. 
DISCUSSION
This study employed a syngeneic transplantation model to test whether exendin-4 treatment improves the outcome of transplantation with marginal number of islets. Previously, we demonstrated that, after syngeneic transplantation with 150 freshly isolated C57BL/6 mouse islets, 18% and 73% achieved normoglycemia at 4 and 12 weeks, respectively (16) . In the present study, after transplantation with this suboptimal number of islets, the blood glucose levels in diabetic recipients decreased progressively. However, the exendin-4-treated group had not only lower blood glucose than controls but also better glucose tolerance at 2 and 4 weeks. By 6 weeks, more (100%) mice treated with exendin-4 than controls (62.5%) achieved euglycemia (p = 0.018). Moreover, the time to obtain normoglycemia was much shorter in mal number of islets improves glycemia, increases the cure rate of diabetes, and reduces the time needed to cure diabetes.
Sharma et al. demonstrated exendin-4 treatment im-group than in controls (Fig. 4) . The graft β-cell mass was 0.30 ± 0.11 mg (0.19-0.41 mg, n = 4) in exendin-proved recipients' metabolic control by transplanting 30 rat islets precultured with exendin-4 to athymic mice 4-treated group and 0.13 ± 0.03 mg (0.11-0.19 mg, n = 5) in controls (p = 0.012). Exendin-4-treated group had and then further treated recipients with exendin-4 after transplantation (32) . In that study, it is difficult to dis-2.3-fold more β-cell mass of the graft that controls. sect the beneficial effects of the exendin-4 treatment in transplanted isolated islets instead of pancreatic clusters, the increased β-cell neogenesis from precursor or stem vitro and in vivo. In contrast, our experiments using freshly isolated mouse islets clearly demonstrate that cells is excluded. It has previously been shown that the first few days of islet transplantation are characterized posttransplant exendin-4 treatment can improve islet recipients' glucose metabolism. However, our results are by dynamic changes, with substantial islet cell dysfunction and death followed by tissue remodeling and then contradictory to those of King et al., who showed posttransplant exendin-4 treatment did not improve glucose stable engraftment (3,6). Thus, exendin-4 may inhibit βcell apoptosis early after islet transplantation and stimu-homeostasis in the recipients initially transplanted with a large number (i.e., 500) of freshly isolated mouse islets late β-cell replication at a later stage. It is also possible that all of the beneficial effects in the exendin-4 group (20). Because we found the exendin-4-treated group had lower blood glucose than controls soon after transplanta-were a consequence of better glycemic control achieved by exendin-4 treatment. Further studies are needed to tion, the duration of exendin-4 treatment (2 vs. 6 weeks) cannot explain these differences. Strict metabolic control learn the mechanisms of exendin-4 on islet grafts. In summary, our findings indicate posttransplant ex-of diabetic animals, either by insulin treatment or by transplantation of additional islets, has been shown to endin-4 treatment can expand graft β-cell mass and improve transplantation outcome in diabetic mice with a enhance the growth and function of the islet graft (1,3,4, 14, 15, 18, 25, 26 ). Thus, it is possible that the bene-marginal number of fresh islets. Recent studies in type 1 diabetes demonstrated that transplanted human islets fit of exendin-4 treatment was masked by the effects of normoglycemic environment achieved by transplanta-retain the ability to response to GLP-1 (10) and exenatide stimulates insulin secretion in islet recipients (12) . tion of a large number of islets. In contrast, our recipients with a marginal number of islets remained hyper-Thus, exendin-4 has clinical potential to increase the success rate of islet transplantation, minimize the num-glycemic for a period after transplantation, so that the exendin-4 could exhibit its advantages.
ber of islets required to reverse diabetes and, hopefully, prolong insulin independence after islet transplantation. Exendin-4 improves glycemic control in type 2 diabetic patients by stimulating glucose-dependent insulin ACKNOWLEDGMENTS: This work was supported by grants secretion and biosynthesis as well as by suppressing glu- the present study, body weight in recipients with and without exendin-4 treatment gradually increased after REFERENCES transplant and the two groups did not significantly differ
